Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study

J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1.
No abstract available

Keywords: Albuvirtide; Fusion inhibitor; HIV; LPV/r; Non-inferiority; Phase 3 clinical trial.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Drug Therapy, Combination
  • HIV Fusion Inhibitors* / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Protease Inhibitors* / therapeutic use
  • HIV-1*
  • Humans
  • Lopinavir / therapeutic use
  • Maleimides
  • Peptides
  • Ritonavir / therapeutic use
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Fusion Inhibitors
  • HIV Protease Inhibitors
  • Maleimides
  • Peptides
  • Lopinavir
  • albuvirtide
  • Ritonavir